Clinical trial
A Phase I Trial to Evaluate Didanosine (ddI) in HIV-Infected Pregnant Women
NCT00000839 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00000839 |
|---|---|
| Title | A Phase I Trial to Evaluate Didanosine (ddI) in HIV-Infected Pregnant Women |
| Official title | A Phase I Trial to Evaluate Didanosine (ddI) in HIV-Infected Pregnant Women |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections, Pregnancy |
| Intervention type | Drug |
| Interventions | Didanosine |
| Enrollment | 12 |
| Completion | Jun 1, 2001 |
| First posted | Aug 31, 2001 |
| Last update posted | Oct 29, 2021 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: